Newly Published RCT Shows MolecuLight Fluorescence Point-of-Care Imaging Improved 12-Week Wound Healing by 204% in Diabetic Foot Ulcers

July 13, 2022 -Study Confirms the Utility of MolecuLight to Inform Clinicians to the Presence and Location of Clinically Significant Bacteria and Improves Treatment Plans & Outcomes over Conventional Diagnostic Methods

Leeds, UK and Toronto, CANADA – (July 13, 2022) MolecuLight Inc., the leader in fluorescence imaging for detection and localization of

… Read More

FDA 510(k) Clearance Expands Labelling of MolecuLight i:X® to Include the Ability to Identify Regions Containing Elevated Load and More Bacterial Species

June 29, 2022 -New FDA Clearance Illustrates the Utility of the i:X to Reliably Detect Clinically Significant Bacteria that Impedes Wound Healing

TORONTO, CANADA – (June 29, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has received an expansion

… Read More

MolecuLight Added to the ISWCAP 2022 Consensus Guidelines for Optimising Prevention of Surgical Wound Complications

June 1, 2022 -Authors of International Consensus Suggest that Fluorescence Imaging of Bacterial Burden is Positioned to Change Contemporary Paradigms of Post-Surgical Wound Management

Toronto, CANADA and London, UK – (June 1, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection and localization of elevated bacterial load in wounds, announced

… Read More

MolecuLight i:X® Receives Regulatory Clearance and Reimbursement in South Korea

April 6, 2022 -KOVE Inc. to Distribute the MolecuLight Product Suite to Large South Korean Wound Care Market

Toronto, CANADA and Seoul, SOUTH KOREA – (April 6, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, and KOVE Inc., announce that the MolecuLight

… Read More

MolecuLight Featured in Unprecedented 32 Presentations and Posters at World Union of Wound Healing Societies (WUWHS) 2022 Conference

March 1, 2022 -Wide-Spread Clinical Evidence using the MolecuLight i:X Platform Reveals its Significant Global Adoption and Proven Utility in Wound Care

Toronto, CANADA and Abu Dhabi, UNITED ARAB EMIRATES – (March 1, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces

… Read More

Latest Clinical Evidence Presented at APWCA’s Wound Week™ 2022 Illustrates the Significant Clinical Utility of the MolecuLight Point-of-Care Imaging Platform

February 24, 2022 -8 Clinical Posters and a Presentation and Hands-On Workshop Highlights the Breadth of Clinical Benefits of the MolecuLight Device for Wound Care Applications

Toronto, ONTARIO and Philadelphia, PENNSYLVANIA – (February 24, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads,

… Read More

New Clinical Study Finds MolecuLight i:X® Point-of-Care Imaging Improved Sensitivity of Detecting Bacterial Burden in Surgical Site Wounds by 11-Fold

January 18, 2022 -Authors Suggest that Fluorescence Imaging of Bacterial Burden is Positioned to Change Contemporary Paradigms of Post-Surgical Wound Management

TORONTO, ONTARIO – (Jan. 18, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication of  “Uncovering

… Read More